ABSTRACT
To justify the use of secondary surgery for recurrent ovarian cancer, several clinical questions must be addressed: (1) What is the potential survival benet of successful secondary cytoreduction and what constitutes an optimal surgical resection? (2) What is the feasibility of a successful resection? (3) What is the associated risk of morbidity and
mortality? (4) Are there clearly dened selection criteria by which to identify patients suitable for this approach? In addition, the clinician must have a working knowledge of the advantages and limitations of currently available surveillance techniques for detecting recurrent disease.
